{"created":"2023-05-15T14:37:19.598466+00:00","id":48131,"links":{},"metadata":{"_buckets":{"deposit":"c370f87c-5342-47cc-a115-3ba297fbc07c"},"_deposit":{"created_by":1,"id":"48131","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"48131"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00048131","sets":["1"]},"author_link":["483315","483311","483312","483318","483314","483316","483308","483317","483307","483319","483313","483310","483309"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2016-11","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"293","bibliographicPageStart":"288","bibliographicVolumeNumber":"121","bibliographic_titles":[{"bibliographic_title":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"BACKGROUND AND PURPOSE:  A multi-institutional observational study (J-CROS1501PR) has been carried out to analyze outcomes of carbon-ion radiotherapy (CIRT) for patients with prostate cancer.\nPATIENTS AND METHODS:  Data of the patients enrolled in prospective studies of following 3 CIRT institutions were analyzed: National Institute of Radiological Sciences (NIRS; Chiba, Japan), Gunma University Heavy Ion Medical Center (GHMC; Gunma, Japan), and Ion Beam Therapy Center, SAGA HIMAT Foundation (HIMAT; Saga, Japan). Endpoints of the clinical trial are biochemical recurrence-free survival (bRFS), overall survival (OS), cause-specific survival (CSS), local control rate (LCR), and acute/late adverse effects.\nRESULTS:  A total of 2157 patients' data were collected from NIRS (n=1432), GHMC (n=515), and HIMAT (n=210). The number of patients in low-risk, intermediate-risk, and high-risk groups was 263 (12%), 679 (31%), and 1215 (56%), respectively. The five-year bRFS in low-risk, intermediate-risk, and high-risk patients was 92%, 89%, and 92%, respectively. The five-year CSS in low-risk, intermediate-risk, and high-risk patients was 100%, 100%, and 99%, respectively. The incidence of grade 2 late GU/GI toxicities was 4.6% and 0.4%, respectively, and the incidence of ⩾G3 toxicities were 0%.\nCONCLUSIONS:  Favorable overall outcomes of CIRT for prostate cancer were suggested by the analysis of the first multi-institutional data.","subitem_description_type":"Abstract"}]},"item_8_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Elsevier Scientific Publishers"}]},"item_8_relation_13":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"27836119","subitem_relation_type_select":"PMID"}}]},"item_8_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1016/j.radonc.2016.10.009","subitem_relation_type_select":"DOI"}}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0167-8140","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Nomiya, Takuma"}],"nameIdentifiers":[{"nameIdentifier":"483307","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsuji, Hiroshi"}],"nameIdentifiers":[{"nameIdentifier":"483308","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kawamura, Hidemasa"}],"nameIdentifiers":[{"nameIdentifier":"483309","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ohno, Tatsuya"}],"nameIdentifiers":[{"nameIdentifier":"483310","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Toyama, Shingo"}],"nameIdentifiers":[{"nameIdentifier":"483311","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Shioyama, Yoshiyuki"}],"nameIdentifiers":[{"nameIdentifier":"483312","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nakayama, Yuko"}],"nameIdentifiers":[{"nameIdentifier":"483313","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nemoto, Kenji"}],"nameIdentifiers":[{"nameIdentifier":"483314","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsujii, Hirohiko"}],"nameIdentifiers":[{"nameIdentifier":"483315","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kamada, Tadashi"}],"nameIdentifiers":[{"nameIdentifier":"483316","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻 比呂志","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"483317","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻井 博彦","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"483318","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鎌田 正","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"483319","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"A multi-institutional analysis of prospective studies of carbon ion radiotherapy for prostate cancer: A report from the Japan Carbon ion Radiation Oncology Study Group (J-CROS).","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"A multi-institutional analysis of prospective studies of carbon ion radiotherapy for prostate cancer: A report from the Japan Carbon ion Radiation Oncology Study Group (J-CROS)."}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-07-20"},"publish_date":"2017-07-20","publish_status":"0","recid":"48131","relation_version_is_last":true,"title":["A multi-institutional analysis of prospective studies of carbon ion radiotherapy for prostate cancer: A report from the Japan Carbon ion Radiation Oncology Study Group (J-CROS)."],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T23:31:35.750331+00:00"}